Philip L. Molyneaux

Philip L. Molyneaux

Auto-generated profile, based on publicly available information

Philip L. Molyneaux

National Heart and Lung Institute, Imperial College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2018 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
LCLindsay J. Celada
Lindsay J. Celada
JKJonathan A. Kropski
Jonathan A. Kropski
JHJose D. Herazo-Maya
Jose D. Herazo-Maya
WLWeifeng Luo
Weifeng Luo
ACAmy Creecy
Amy Creecy
WDWonder Drake
Wonder Drake
PD-1 + T H 17 cells enhance collagen-1 production from human lung fibroblasts.

19 November 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
NHNikhil Hirani
Nikhil Hirani
AMAlison C. MacKinnon
Alison C. MacKinnon
LNLisa Nicol
Lisa Nicol
PFPaul Ford
Paul Ford
HSHans Schambye
Hans Schambye
TMToby M. Maher
Toby M. Maher
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3.A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled TD139 in 36 healthy subjects and 24 patients with IPF. Six dose cohorts of six healthy subjects were evaluated (4:2 TD139:placebo ratio) with single doses of TD139 (0.15–50 mg) and three dose cohorts of eight patients with IPF (5:3 TD139:placebo ratio) with once-daily doses of TD139 (0.3–10 mg) for 14 days.Inhaled TD139 was well tolerated with no significant treatment-related side-effects. TD139 was rapidly absorbed, with mean time taken to reach maximum plasma concentration (Cmax) values ranging from 0.6 to 3 h and a plasma half-life (T1/2) of 8 h. The concentration of TD139 in the lung was >567-fold higher than in the blood, with systemic exposure predicting exposure in the target compartment. Gal-3 expression on alveolar macrophages was reduced in the 3 and 10 mg dose groups compared with placebo, with a concentration-dependent inhibition demonstrated. Inhibition of Gal-3 expression in the lung was associated with reductions in plasma biomarkers centrally relevant to IPF pathobiology (platelet-derived growth factor-BB, plasminogen activator inhibitor-1, Gal-3, CCL18 and YKL-40).TD139 is safe and well tolerated in healthy subjects and IPF patients. It was shown to suppress Gal-3 expression on bronchoalveolar lavage macrophages and, in a concerted fashion, decrease plasma biomarkers associated with IPF progression.

15 June 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
PMPhilip L. Molyneaux
Philip L. Molyneaux
SWSaffron A. G. Willis-Owen
Saffron A. G. Willis-Owen
MCMichael J. Cox
Michael J. Cox
PJPhillip James
Phillip James
SCSteven Cowman
Steven Cowman
TMToby M. Maher
Toby M. Maher
Rationale: Changes in the respiratory microbiome are associated with disease progression in idiopathic pulmonary fibrosis (IPF). The role of the host response to the respiratory microbiome remains unknown. Objectives: To explore the host–microbial interactions in IPF. Methods: Sixty patients diagnosed with IPF were prospectively enrolled together with 20 matched control subjects. Subjects underwent bronchoalveolar lavage (BAL), and peripheral whole blood was collected into PAXgene tubes for all subjects at baseline. For subjects with IPF, additional samples were taken at 1, 3, and 6 months and (if alive) 1 year. Gene expression profiles were generated using Affymetrix Human Gene 1.1 ST arrays. Measurements and Main Results: By network analysis of gene expression data, we identified two gene modules that strongly associated with a diagnosis of IPF, BAL bacterial burden (determined by 16S quantitative polymerase chain reaction), and specific microbial operational taxonomic units, as well as with lavage and peripheral blood neutrophilia. Genes within these modules that are involved in the host defense response include NLRC4, PGLYRP1, MMP9, and DEFA4. The modules also contain two genes encoding specific antimicrobial peptides (SLPI and CAMP). Many of these particular transcripts were associated with survival and showed longitudinal overexpression in subjects experiencing disease progression, further strengthening the relationship of the transcripts with disease. Conclusions: Integrated analysis of the host transcriptome and microbial signatures demonstrated an apparent host response to the presence of an altered or more abundant microbiome. These responses remained elevated in longitudinal follow-up, suggesting that the bacterial communities of the lower airways may act as persistent stimuli for repetitive alveolar injury in IPF.

20 March 2020 in Immunology
Verified
Journal Article
Open access
PDF file
RIRachele Invernizzi
Rachele Invernizzi
CLClare M. Lloyd
Clare M. Lloyd
PMPhilip L. Molyneaux
Philip L. Molyneaux
Summary: The airway epithelium represents a physical barrier to the external environment acting as the first line of defence against potentially harmful environmental stimuli including microbes and allergens. However, lung epithelial cells are increasingly recognized as active effectors of microbial defence, contributing to both innate and adaptive immune function in the lower respiratory tract. These cells express an ample repertoire of pattern recognition receptors with specificity for conserved microbial and host motifs. Modern molecular techniques have uncovered the complexity of the lower respiratory tract microbiome. The interaction between the microbiota and the airway epithelium is key to understanding how stable immune homeostasis is maintained. Loss of epithelial integrity following exposure to infection can result in the onset of inflammation in susceptible individuals and may culminate in lung disease. Here we discuss the current knowledge regarding the molecular and cellular mechanisms by which the pulmonary epithelium interacts with the lung microbiome in shaping immunity in the lung. Specifically, we focus on the interactions between the lung microbiome and the cells of the conducting airways in modulating immune cell regulation, and how defects in barrier structure and function may culminate in lung disease. Understanding these interactions is fundamental in the search for more effective therapies for respiratory diseases.

26 January 2022 in Immunity
Verified
Journal Article
Open access
BVBavithra Vijayakumar
Bavithra Vijayakumar
KBKarim Boustani
Karim Boustani
POPatricia P. Ogger
Patricia P. Ogger
APArtemis Papadaki
Artemis Papadaki
JTJames Tonkin
James Tonkin
JHJames A. Harker
James A. Harker
Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for many months. We delineated the immune-proteomic landscape in the airways and peripheral blood of healthy controls and post-COVID-19 patients 3 to 6 months after hospital discharge. Post-COVID-19 patients showed abnormal airway (but not plasma) proteomes, with an elevated concentration of proteins associated with apoptosis, tissue repair, and epithelial injury versus healthy individuals. Increased numbers of cytotoxic lymphocytes were observed in individuals with greater airway dysfunction, while increased B cell numbers and altered monocyte subsets were associated with more widespread lung abnormalities. A one-year follow-up of some post-COVID-19 patients indicated that these abnormalities resolved over time. In summary, COVID-19 causes a prolonged change to the airway immune landscape in those with persistent lung disease, with evidence of cell death and tissue repair linked to the ongoing activation of cytotoxic T cells.

8 October 2020 in Science Immunology
Verified
Journal Article
Closed access
POPatricia P. Ogger
Patricia P. Ogger
GAGesa Albers
Gesa Albers
RHRichard J. Hewitt
Richard J. Hewitt
BOBrendan J. O’sUllivan
Brendan J. O’sUllivan
JPJoseph E. Powell
Joseph E. Powell
ABAdam J. Byrne
Adam J. Byrne
The ACOD1/itaconate axis is a pulmonary regulatory pathway that controls the severity of fibrosis and is a potential therapeutic target in IPF.